Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 2 for:    gateway institute for brain research
Previous Study | Return to List | Next Study

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease (NOSE-PD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05266417
Recruitment Status : Recruiting
First Posted : March 4, 2022
Last Update Posted : April 22, 2022
Information provided by (Responsible Party):
Gateway Institute for Brain Research

Brief Summary:
This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: INS-GSH Drug: Matched Placebos Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD)
Actual Study Start Date : February 7, 2022
Estimated Primary Completion Date : February 28, 2024
Estimated Study Completion Date : August 30, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Active
Insulin (Novolin R) and Glutathione (INS-GSH)
Intranasal INS-GSH Twice Daily

Placebo Comparator: Control
Drug: Matched Placebos
Intranasal Matched Placebos Twice Daily
Other Name: Insulin Matched Placebo and Glutathione Matched Placebo

Primary Outcome Measures :
  1. Verbal Fluency [ Time Frame: 24 Weeks ]
    F, A and S (FAS) words test

Secondary Outcome Measures :
  1. Verbal Fluency [ Time Frame: 28 Weeks ]
    Change in verbal fluency as assessed by the FAS test

  2. Motor Function [ Time Frame: 24 Weeks ]
    Change in Timed Up and Go (TUG) test

  3. Motor Function [ Time Frame: 24 Weeks ]
    Change in the updated Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III total score

  4. Motor Function [ Time Frame: 24 Weeks ]
    Change in the updated MDS-UPDRS total score

  5. Motor Function [ Time Frame: Week 24 ]
    Change in the Clinical Global Impression (CGI) score

  6. Motor Function [ Time Frame: Week 24 ]
    Change in Clinical Impression of Severity Index for Parkinson's Disease (CISI-PD)

  7. Cognitive Function [ Time Frame: Week 24 ]
    Change in each of the individual twelve (12) task standardized scores assessed using the Cambridge Brain Sciences (CBS) computerized neuropsychological battery

  8. Non-Motor Function [ Time Frame: Week 24 ]
    Change in Hamilton Rating Scale for Depression total score

  9. Patient Reported Outcome [ Time Frame: Week 24 ]
    Change in Parkinson's Disease Quality of Life Questionnaire (PDQ-39) assessment

  10. Patient Reported Outcome [ Time Frame: Week 24 ]
    Change in the Patient Global Impression (PGI) score

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Documented clinical diagnosis of idiopathic PD
  • Modified HY stage < 5
  • Able to administer study drug or have a caregiver throughout the duration of the study to help administer drug
  • Willing to continue diet, exercise and medications reported at baseline consistently throughout participation in the trial. Essential changes are permitted
  • If taking PD medications or any nutraceuticals, must be on a stable dose for at least 30 days prior to Screening Visit. Essential changes will be permitted.
  • If subject is taking chronic antidepressant or an anxiolytic, must be on a stable dose for at least 90 days prior to Screening. Essential changes will be permitted.

Key Exclusion Criteria:

  • Clinical diagnosis of Type 1 or Type 2 Diabetes Mellitus
  • Glycated hemoglobin (HbA1c) level ≥ 6.5%
  • History of hypoglycemia and/or documented plasma glucose levels of ≤ 50 mg/dL with or without symptoms of hypoglycemia
  • Mini-Mental State Exam (MMSE) score of ≤ 24 at Screening
  • Positive COVID-19 test at Screening and/or within 30 days of Screening
  • Change in or escalation of dose of a chronic therapeutic agent that has the potential to impair cognitive functioning
  • Chronic inflammation of nasal cavity that may prevent absorption of study treatments
  • Insufficiently controlled respiratory disease (i.e., asthma, COPD).
  • History of any significant neurologic or psychiatric disease other than PD
  • Current diagnosis of epilepsy and had a history of seizures as an adult within 1 year of Screening, or unexplained recent loss of consciousness, or history of significant head trauma with loss of consciousness
  • History of non-lacunar ischemic and/or hemorrhagic stroke
  • Unstable or uncontrolled cardiac disease that could expose the subject to additional safety risks
  • Use of the following medications: Insulin or any other anti-hyperglycemic agent(s) except if used during isolated gestational diabetes, Supplementation with GSH or any medication shown to increase glutathione, and Beta Blockers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05266417

Layout table for location contacts
Contact: Thomas Freeman (954) 636-2166
Contact: Vanesa Aday (954) 636-2166

Layout table for location information
United States, Florida
Institute for Neuroimmune Medicine Recruiting
Davie, Florida, United States, 33314
Contact: Irina Rozenfeld, DN         
Sponsors and Collaborators
Gateway Institute for Brain Research
Layout table for additonal information
Responsible Party: Gateway Institute for Brain Research Identifier: NCT05266417    
Other Study ID Numbers: 20-GTY-008-01
First Posted: March 4, 2022    Key Record Dates
Last Update Posted: April 22, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Gateway Institute for Brain Research:
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Hypoglycemic Agents
Physiological Effects of Drugs